{"entity":{"id":"edigene","kind":"company","name":"EdiGene","aka":["博雅辑因","EdiGene (Beijing) Biotechnology"],"tldr":"EdiGene is a Beijing gene-editing company. It is developing donor-derived CAR-T cells for B-cell lymphoma and solid tumours, runs a screening system that edits genes at scale to find drug targets, and edits RNA inside the body for inherited diseases.","summary":"EdiGene (Beijing) Biotechnology was established in May 2015 and focuses on original gene-editing work for cell and gene therapies. Its website describes three platforms: a high-throughput genome-editing screening platform for targeted therapy, MAGIC, an allogeneic cell therapy platform, and LEAPER, an in vivo RNA base-editing platform. The MAGIC pipeline lists allogeneic CAR-T therapies for relapsed or refractory B-cell non-Hodgkin lymphoma, for solid tumours and for autoimmune disease, and an allogeneic stem-cell-derived therapy. The LEAPER programmes are for Duchenne muscular dystrophy, Usher syndrome type II and alpha-1 antitrypsin deficiency liver disease. The company lists an April 2022 cooperation with Peking University Cancer Hospital.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://www.edigene.com/"},{"label":"Company overview (founded May 2015)","url":"https://www.edigene.com/company_overview/"},{"label":"Pipeline","url":"https://www.edigene.com/our_pipeline/"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":["cell-therapy","drug-discovery"],"technologies":["allogeneic-cell-therapy","car-t","crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The website describes the screening platform as high-throughput genome-editing screening without naming CRISPR; it is linked to the CRISPR screens technology on that basis. The stage of each programme could not be read from the pipeline page, so none is given. Founders are not named on the pages read. Headquarters is inferred from the registered company name, EdiGene (Beijing) Biotechnology Co., Ltd.; the company says it has offices in four cities without naming them. The English site redirects to a host with an expired certificate and was not read. No listing or financing is recorded."],"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.edigene.com/","founded":2015,"investors":[],"funding":[]},"route":"/companies/edigene/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"}]}}